Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Fungal Allergenic Extract [EPC]
Juglans Cinerea Branch Bark/root Bark is a non-standardized allergenic extract used primarily in the diagnosis and treatment of specific IgE-mediated hypersensitivities. It belongs to the class of plant-derived allergenic extracts used in skin testing and subcutaneous immunotherapy.
Name
Juglans Cinerea Branch Bark/root Bark
Raw Name
JUGLANS CINEREA BRANCH BARK/ROOT BARK
Category
Non-Standardized Fungal Allergenic Extract [EPC]
Drug Count
5
Variant Count
11
Last Verified
February 17, 2026
About Juglans Cinerea Branch Bark/root Bark
Juglans Cinerea Branch Bark/root Bark is a non-standardized allergenic extract used primarily in the diagnosis and treatment of specific IgE-mediated hypersensitivities. It belongs to the class of plant-derived allergenic extracts used in skin testing and subcutaneous immunotherapy.
Detailed information about Juglans Cinerea Branch Bark/root Bark
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Juglans Cinerea Branch Bark/root Bark.
Juglans Cinerea Branch Bark/root Bark, derived from the White Walnut or Butternut tree, is a specialized biological product classified as a Non-Standardized Plant Allergenic Extract. In the realm of clinical immunology, this substance is utilized to identify and treat allergic sensitizations. It belongs to a broader class of drugs known as allergenic extracts, which are complex mixtures of proteins, glycoproteins, and polysaccharides derived from natural sources. These extracts are essential tools for allergists to diagnose Type I hypersensitivity reactions (immediate-type allergies) and to perform allergen-specific immunotherapy (SIT).
According to the FDA’s regulatory framework, Juglans Cinerea extracts are categorized as 'non-standardized.' This means that unlike 'standardized' extracts (such as those for ragweed or certain grass pollens), there is no federally mandated bioequivalent potency test or internal standard for every lot. Instead, the potency is typically expressed in terms of Weight/Volume (W/V) or Protein Nitrogen Units (PNU). Despite this classification, these extracts are manufactured under strict Current Good Manufacturing Practices (cGMP) to ensure consistency and safety for clinical use.
The pharmacological action of Juglans Cinerea extract depends on its application: diagnostic or therapeutic. At the molecular level, the extract contains specific antigenic determinants (epitopes) that are recognized by the patient's immune system.
Diagnostic Mechanism: When applied via skin prick testing (SPT) or intradermal testing (IDT), the allergens in the extract cross-link specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells in the skin. This cross-linking triggers mast cell degranulation, releasing inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This results in a localized 'wheal and flare' reaction—a raised bump surrounded by redness—which is measured by the healthcare provider to confirm sensitization.
Therapeutic Mechanism (Immunotherapy): When used in subcutaneous immunotherapy (SCIT), the extract is administered in gradually increasing doses. This process, known as desensitization or hyposensitization, induces immune tolerance. It shifts the immune response from a Th2-dominated (allergic) profile to a Th1-dominated or T-regulatory (Treg) profile. This leads to the production of 'blocking antibodies' (IgG4), which compete with IgE for allergen binding, and a decrease in the recruitment of eosinophils and basophils to the shock organs (like the nose or lungs).
Traditional pharmacokinetic studies (absorption, distribution, metabolism, and excretion) are not typically performed for allergenic extracts like Juglans Cinerea because they are biological mixtures rather than discrete chemical entities. However, their clinical behavior follows established immunological pathways:
Juglans Cinerea Branch Bark/root Bark extract is indicated for several specific clinical applications in the field of allergy and immunology:
Juglans Cinerea Branch Bark/root Bark is primarily available in the following formats:
> Important: Only your healthcare provider can determine if Juglans Cinerea Branch Bark/root Bark is right for your specific condition.
Dosage for Juglans Cinerea Branch Bark/root Bark is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels and clinical history. There is no standard 'one-size-fits-all' dose.
Juglans Cinerea allergenic extracts are generally considered safe for use in children, provided the dosage is carefully titrated. Pediatric dosing follows the same principles as adult dosing, starting with very low concentrations and increasing based on tolerance. However, children under the age of 5 may be less cooperative with the injection schedule, and the risk-benefit ratio must be carefully evaluated by a pediatric allergist. There is no specific age-based dosage adjustment; the 'dose' is based on the individual's immunological threshold.
No specific dosage adjustments are required for patients with renal impairment, as the systemic protein load from the extract is negligible. However, patients with severe renal disease should be monitored for their ability to tolerate potential systemic reactions.
No dosage adjustments are necessary for patients with hepatic impairment. The metabolism of allergenic proteins does not rely on primary hepatic pathways like the CYP450 system.
Caution should be exercised in elderly patients, particularly those with underlying cardiovascular disease. The use of epinephrine (the primary treatment for a severe reaction) may be more risky in this population. Healthcare providers may opt for a more conservative build-up schedule.
This medication is never self-administered by the patient at home. It must be administered in a clinical setting equipped to handle anaphylaxis.
If a dose in the immunotherapy build-up phase is missed, the next dose may need to be reduced or the previous dose repeated to maintain safety. If the gap between doses is too long (e.g., several weeks), the entire schedule may need to be restarted at a lower concentration. Consult your allergist immediately if you miss an appointment.
An overdose of allergenic extract (either through a calculation error or a sudden increase in the patient's sensitivity) typically manifests as a severe systemic allergic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing skin testing or immunotherapy with Juglans Cinerea Branch Bark/root Bark will experience localized reactions. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Juglans Cinerea Branch Bark/root Bark and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
There are no known long-term 'toxic' effects of Juglans Cinerea allergenic extracts on organ systems like the liver or kidneys. The primary long-term risk is the development of new sensitivities or the persistence of local skin changes at the injection sites. Some studies have looked into the theoretical risk of autoimmune issues, but no definitive link has been established in decades of clinical use of allergenic extracts.
While Juglans Cinerea Branch Bark/root Bark may not have an individual black box warning for every manufacturer, the class of allergenic extracts carries a general warning regarding Anaphylaxis.
Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma are at higher risk for severe reactions. Injections must be administered in a facility equipped to treat anaphylaxis, and patients must be observed for at least 30 minutes. Patients should be informed of the signs and symptoms of severe reactions and instructed on how to use an epinephrine auto-injector if a delayed reaction occurs.
Report any unusual symptoms to your healthcare provider.
Juglans Cinerea Branch Bark/root Bark is a potent biological substance. Its use is restricted to physicians trained in the diagnosis and treatment of allergic diseases. The most critical safety consideration is the risk of a systemic allergic reaction, which can occur even in patients who have previously tolerated the extract well.
No FDA black box warnings specifically for Juglans Cinerea Branch Bark/root Bark, but it falls under the general safety mandates for all allergenic extracts. These mandates emphasize that the product is not for intravenous use and must only be administered subcutaneously by trained personnel. The risk of sudden, severe, and potentially fatal anaphylaxis is the primary concern highlighted in the clinical literature and FDA-approved labeling for the class.
No routine laboratory monitoring (like blood counts or liver enzymes) is required for this extract. However, clinical monitoring is intensive:
Most patients can drive or operate machinery after the 30-minute observation period. However, if a patient experiences significant fatigue or a mild systemic reaction (like dizziness or hives), they should refrain from these activities until symptoms fully resolve.
There is no direct chemical interaction between alcohol and Juglans Cinerea extract. However, alcohol consumption can cause vasodilation and may theoretically increase the rate of allergen absorption or mask the early symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours before and after an injection.
Discontinuing Juglans Cinerea immunotherapy does not cause a 'withdrawal syndrome' in the traditional sense. However, the patient's allergic symptoms may gradually return if the course of treatment was not completed (usually 3 to 5 years). Tapering is not required when stopping the medication.
> Important: Discuss all your medical conditions with your healthcare provider before starting Juglans Cinerea Branch Bark/root Bark.
There are few absolute drug-drug contraindications, but certain combinations are avoided due to safety concerns:
There are no known direct food interactions that affect the metabolism of Juglans Cinerea extract. However, if a patient has a known food allergy to walnuts (which are related to Juglans Cinerea), they must inform their doctor, as the extract may trigger a cross-reactive systemic response.
There is limited data on herbal interactions. However, supplements with known anti-inflammatory or antihistamine-like properties (e.g., Butterbur, Quercetin, or high-dose Vitamin C) could theoretically dampen the results of a diagnostic skin test. It is best to disclose all supplements to the allergist.
Juglans Cinerea extract does not typically interfere with standard blood chemistry or hematology tests. Its primary 'interaction' is with the Skin Prick Test itself. It may also increase the levels of allergen-specific IgG4 in the blood, which is a marker of immunotherapy efficacy rather than a 'test interference.'
For each major interaction, the mechanism is usually related to the pharmacodynamic response (how the body reacts to the allergen or the emergency medication) rather than the pharmacokinetic clearance of the extract.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Juglans Cinerea Branch Bark/root Bark must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the physician:
Patients who are allergic to other members of the Juglandaceae family (such as Black Walnut, English Walnut, or Pecan) are highly likely to react to Juglans Cinerea Branch Bark/root Bark. Cross-reactivity is common among tree pollens and nut-producing trees. A thorough history of food and environmental allergies is essential before administration.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Juglans Cinerea Branch Bark/root Bark.
Pregnancy Category C: No adequate and well-controlled studies have been conducted in pregnant women. The primary risk of Juglans Cinerea extract during pregnancy is not direct teratogenicity (birth defects) but the risk of maternal anaphylaxis. A severe allergic reaction can lead to uterine contractions and placental insufficiency, potentially causing fetal hypoxia or miscarriage.
It is not known whether the allergenic components of Juglans Cinerea extract are excreted in human milk. However, because these are large proteins and the total dose is very small, it is highly unlikely that they would reach the infant in significant quantities or cause harm. Breastfeeding is generally considered safe for women receiving immunotherapy.
Allergenic extracts are used in children as young as 3 to 5 years old. The main challenge in the pediatric population is the child's ability to communicate early symptoms of a systemic reaction. Pediatric patients must be closely monitored by staff experienced in child-specific anaphylaxis protocols. Immunotherapy can be particularly beneficial in children to prevent the 'allergic march' (the progression from rhinitis to asthma).
Elderly patients (over 65) may have a higher prevalence of comorbid conditions like coronary artery disease or COPD, which increases the risk of complications from a systemic reaction. Additionally, the elderly are more likely to be on medications like beta-blockers or ACE inhibitors. A more cautious approach to dosing and a longer observation period may be warranted.
There are no specific guidelines for renal impairment. Since the extract is composed of proteins that are naturally degraded, renal clearance is not a limiting factor for the 'drug' itself, but rather for the clearance of inflammatory mediators if a reaction occurs.
No adjustments are needed for hepatic impairment. The liver does not play a primary role in the immunological processing of subcutaneous allergenic extracts.
> Important: Special populations require individualized medical assessment.
Juglans Cinerea Branch Bark/root Bark extract works through the induction of immunological changes. In diagnostic testing, it relies on the Type I Hypersensitivity pathway. The allergens (proteins) bind to IgE antibodies on mast cells, causing the release of histamine. In therapeutic use (immunotherapy), the mechanism involves:
| Parameter | Value |
|---|---|
| Bioavailability | Not applicable (local/subcutaneous) |
| Protein Binding | Interacts with specific IgE/IgG antibodies |
| Half-life | Proteins degraded within hours; immune effect lasts years |
| Tmax | 15-30 minutes for skin reaction |
| Metabolism | Proteolysis by tissue and plasma enzymes |
| Excretion | Renal (as small peptide fragments) |
Juglans Cinerea extract is a sterile liquid containing the water-soluble components of the branch and root bark. It contains a complex mixture of proteins, including vicilins and legumins, which are the primary allergens. It may also contain tannins and juglone, though these are typically minimized in refined allergenic extracts. The molecular weight of the active allergenic proteins typically ranges from 10 to 70 kDa.
It is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the same therapeutic family as other tree pollen extracts (e.g., Oak, Maple, Birch) used in allergy medicine.
Medications containing this ingredient
Common questions about Juglans Cinerea Branch Bark/root Bark
Juglans Cinerea Branch Bark/root Bark extract is primarily used by allergists to diagnose and treat allergies related to the White Walnut or Butternut tree. For diagnosis, it is applied to the skin to see if a 'wheal and flare' reaction occurs, indicating an allergy. For treatment, it is used in 'allergy shots' (immunotherapy) to help the body build up a tolerance to the allergen over time. This can significantly reduce symptoms like sneezing, itchy eyes, and asthma caused by exposure to the tree's pollen or proteins. It is most often prescribed when standard allergy medications do not provide enough relief.
The most common side effects are localized to the area where the extract was applied or injected. During skin testing, you can expect an itchy, red bump that looks like a mosquito bite, which usually goes away within an hour. For those receiving immunotherapy injections, it is very common to have redness, itching, or a small hard lump at the injection site that can last for a day or two. Some patients may also experience mild 'hay fever' symptoms like sneezing or a stuffy nose shortly after the injection. These local reactions are generally considered a normal part of the treatment process.
It is generally recommended to avoid alcohol on the days you receive an injection of Juglans Cinerea extract. While there is no direct chemical interaction, alcohol can cause your blood vessels to dilate, which might speed up the absorption of the allergen into your bloodstream and increase the risk of a systemic reaction. Alcohol can also make it harder for you to notice the early warning signs of an allergic reaction, such as feeling flushed or dizzy. To ensure maximum safety, most doctors suggest waiting at least 24 hours after your injection before consuming alcohol. Always follow the specific guidance provided by your allergy clinic.
The safety of starting Juglans Cinerea immunotherapy during pregnancy has not been established, and most allergists will not begin the treatment for a pregnant patient. The main concern is not that the extract itself causes birth defects, but that a severe allergic reaction (anaphylaxis) could be dangerous for the baby. If you are already on a stable maintenance dose and become pregnant, your doctor may decide to continue the injections at the same dose, as the risk of a reaction is lower once you are stabilized. You should notify your allergist immediately if you become pregnant so they can adjust your treatment plan. The goal is always to balance symptom control with the safety of the pregnancy.
When used for diagnostic skin testing, the extract works almost immediately, with results visible within 15 to 20 minutes. However, when used as a treatment (immunotherapy), it takes much longer to see a clinical benefit. Most patients begin to notice a reduction in their allergy symptoms after 3 to 6 months of regular injections as they reach higher doses. The full benefits are typically realized after 12 months of consistent treatment. To achieve long-lasting protection that continues even after the injections stop, a full course of 3 to 5 years is usually recommended by specialists.
Yes, you can stop the injections suddenly without experiencing any withdrawal symptoms or physical illness. Unlike some medications that require tapering, allergenic extracts do not create a physical dependence. However, if you stop the treatment before completing the recommended 3-to-5-year course, your allergy symptoms are likely to return over time. You will lose the 'immune tolerance' that the shots were helping you build. If you need to stop treatment due to side effects or lifestyle changes, it is best to discuss this with your allergist to see if an alternative treatment plan is available.
If you miss a scheduled immunotherapy injection, you should contact your allergy clinic as soon as possible to reschedule. Missing a dose can affect your 'build-up' schedule, and your doctor may need to repeat the previous dose or even reduce the dose for your next visit to ensure safety. The longer the gap between injections, the more likely your body is to lose some of its tolerance, which increases the risk of a reaction when you resume. Do not attempt to 'double up' on doses or change your schedule without professional medical supervision. Consistency is key to the success of the treatment.
There is no clinical evidence to suggest that Juglans Cinerea Branch Bark/root Bark extract causes weight gain. The extract consists of a very small amount of protein and is administered in tiny volumes (usually less than 0.5 mL). It does not contain hormones, steroids, or calories that would affect your metabolism or appetite. If you experience weight changes while on immunotherapy, it is likely due to other factors, such as other medications you may be taking (like oral corticosteroids for asthma) or changes in your lifestyle. Always discuss any unexpected physical changes with your healthcare provider.
While it can be taken alongside many medications, some drugs can interfere with its safety or effectiveness. Antihistamines must be stopped before skin testing because they can block the reaction and lead to a false negative result. More importantly, drugs like beta-blockers (used for blood pressure) can make it very difficult to treat a severe allergic reaction if one occurs. Other medications like ACE inhibitors or certain antidepressants may also increase the risk of complications. It is vital that you provide your allergist with a complete and updated list of all prescription and over-the-counter medications you are taking.
The concept of 'generic' vs. 'brand name' is a bit different for allergenic extracts. Juglans Cinerea extract is produced by several different biological laboratories (such as Greer, ALK, or HollisterStier). While they all contain the same active ingredient (the bark extract), they are considered 'non-standardized,' meaning there can be slight variations in potency between different manufacturers. Most insurance companies cover these extracts as specialized biological products. Your allergist will typically stick with one manufacturer for your entire course of treatment to ensure consistency in your dosing.